HRTX Heron Therapeutics Inc Earnings per share for the last twelve months

HRTX (Heron) - company brandmark

Heron Therapeutics (HRTX) has earned physician recognition for its effective pain management and support for oncology patients. The trailing 12-month earnings per share trend shows peak values, after which the current metric equals -0.11. The business is currently focusing on expanding its presence in US hospitals. Meanwhile, the issuer's financial stability remains the norm, ensuring full coverage of all operating expenses.

HRTX (Heron Therapeutics) Net earnings per share for the last 12 months history from 07/04/2022 to 11/18/2026

Heron Therapeutics - analytical breakdowns and key metrics (HRTX)

- current quotes and average value forecast:
Basic company analysis:Heron (HRTX)
Mass-produced product of Heron Therapeutics Inc

Heron Therapeutics (HRTX) monetizes the integration of its drugs into hospital protocols, ensuring sustainable demand and a steady capital inflow. The EPS TTM calculation logic reflects the final net income allocated per share over the year, allowing investors to assess real business efficiency without accounting for capital dilution. A decline in the 12-month EPS trend signals margin erosion and an impending drop in share prices.

Analysis of competing companies

INCY - Earnings per share for the last twelve months|HCM (HUTCHMED) - Earnings per share for the last 12 months|Nuvation Bio Inc. (NUVB) - Earnings per share for the last twelve months|Earnings per share for the last 12 months DAWN|MNPR (monopartx.com) - Net earnings per share (EPS TTM)|Net earnings per share for the last 12 months inhibrx.com (INBX)|Earnings per share for the last twelve months I-Mab (IMAB)|FENC - Net earnings per one share for the last twelve months|Earnings per share for the last twelve months Nuvectis NVCT|Coherus Biosciences - Earnings per share for the last twelve months|CRBP - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months cardiffoncology.com|BYSI: Net earnings per share (EPS TTM)|Net earnings per share for the trailing year BioAtla, Inc. BCAB|Net earnings per share for the last 12 months LIXT|Net earnings per one share for the last twelve months Citius Pharmaceuticals, Inc. CTXR|Net earnings per share for the last 12 months CLRB (Cellectar Biosciences)|BLRX (BioLineRx) - Earnings per share for the trailing year|Can-Fite BioPharma - Net earnings per share for the last 12 months|Earnings per share for the last four quarters APRE (Aprea)|Kazia Therapeutics Limited - Net earnings per share (EPS TTM)|Earnings per share for the trailing year SLXN (silexion.com)|NCNA: Net earnings per share (EPS TTM)|Net earnings per one share for the last twelve months chimerix.com (CMRX)|Earnings per share for the last twelve months Cyclacel|GTHX: Earnings per share for the trailing year|Net earnings per share (EPS TTM) KRON|Net earnings per share (EPS TTM) Kintara Pharma (KTRA)|Earnings per share for the last twelve months Oncternal ONCT|PRTG (Portage Biotech) - Earnings per one share for the last 12 months